Phase I/II STOMP Trial: Selinexor, Pomalidomide, and Dexamethasone in R/R MM

December 7-10, 2019; Orlando, Florida
An all-oral regimen of selinexor + pomalidomide + low-dose dexamethasone appears to be safe and highly active in patients with heavily pretreated MM, warranting further evaluation.
Format: Microsoft PowerPoint (.ppt)
File Size: 197 KB
Released: December 13, 2019


Provided by the Annenberg Center for Health Sciences at Eisenhower in partnership with Clinical Care Options.

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)

Supported by educational grants from
Celgene Corporation
Dova Pharmaceuticals, Inc.
Karyopharm Therapeutics
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company
Pharmacyclics LLC, an AbbVie Company
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Related Content

Key clinical insights from Drs Suzanne Lentzsch and Saad Usmani on individualizing care for patients with MM, from Clinical Care Options (CCO)

Suzanne Lentzsch, MD, PhD Saad Z. Usmani, MD, MBA, FACP Released: June 17, 2021

In this slideset from Clinical Care Options (CCO), experts provide insights on CAR T-cell strategies for myeloma

Noopur Raje, MD Released: June 16, 2021

From Clinical Care Options (CCO), video featuring expert insights on the integration of CAR T-cell therapy into community care

person default Caron A. Jacobson, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: June 14, 2021 Expired: June 13, 2022

Results of the MagnetisMM-1 phase I trial of subcutaneous elranatamab in patients with relapsed/refractory multiple myeloma from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 14, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.